Expanding Psych

Expanding Psych

By KTHealth & FitnessMental Health
Download on the App Store

Expanding Psych episodes

  • Episode 6: Psilocybin Use in Major Depression

    In this episode we take a look at a recent publication which has had a media field day. Claims of psilocybin being four times as effective as typical antidepressant medications have run rampant. Does the data from this study really support a conclusion of that magnitude? If you would like to read the studies cited in the cast they can be found here:

    Madsen (2019) - https://www.nature.com/articles/s41386-019-0324-9

    Williams (2008) - https://pubmed.ncbi.nlm.nih.gov/18408526/

    Davis (2020) - https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630

    Kennedy (2016) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994790/

    Dinis-Oliveira - https://pubmed.ncbi.nlm.nih.gov/28074670/

    Fournier (2010) - https://pubmed.ncbi.nlm.nih.gov/20051569/

    Dimidjian (2006) - https://pubmed.ncbi.nlm.nih.gov/16881773/

    19 min
  • Episode 5: LSD Across the Decades

    In this episode we explore the development of studies examining Lysergic Acid Diethylamide (LSD) in various psychiatric conditions. From its synthesis in 1938 this chemical has garnered equal parts mysticism and criticism. Entering into the early 1970's many studies which were beginning to characterize LSD and its profound psychological effects ceased as the war on drugs hit back with full force. As a result over the last five decades there has been little in the way of progress. A newfound 'psychedelic renaissance' has re-ignited interest in LSD as a potential therapeutic in a myriad of psychiatric conditions. Most trials of the drug are still in their infancy so getting a good amount of foundational knowledge will be key to understanding developments in the future. If you would like to read the studies cited in the cast they can be found here: 

    Lipari & Jean-Francois (2016) - https://www.samhsa.gov/data/sites/default/files/report_2418/ShortReport-2418.html 

    Yockley et al. (2020) - https://www.sciencedirect.com/science/article/abs/pii/S0376871620302362 

    Schmid et al. (2015) - https://pubmed.ncbi.nlm.nih.gov/25575620/ 

    Kuypers et al. (2020) - https://pubs.acs.org/doi/10.1021/acsptsci.0c00099 

    Liechti et al. (2018) - https://www.sciencedirect.com/science/article/pii/S2213158218300755 

    Fuentes et al. (2020) - https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00943/full 

    Schmid & Liechti (2017) - https://pubmed.ncbi.nlm.nih.gov/28918441/ 

    Nutt, Carhart-Harris & Roseman (2018) - https://www.frontiersin.org/articles/10.3389/fphar.2017.00974/full


    Holze et al. (2020) - https://www.nature.com/articles/s41386-020-00883-6 

    18 min
  • Episode 4: Psilocybin Approved for Clinical Use Under Section 56 Exemption
    In this episode we take a look at the recent section 56 exemption approved by Health Canada for psilocybin use in four terminally ill cancer patients. This approval represents a huge step forward in the treatment of mental health disorders and could have some interesting implications.
    Link to my October 2019 paper: https://www.docdroid.net/CmPlLos/marijuana-as-an-entryway-to-psychedelic-therapy-docx
    10 min
  • Episode 3: Current Therapies in Mental Health and the Accelerating Need for Innovation
    In this episode we examine what the current landscape of mental health therapies looks like along with the pressures of the current global health climate in terms of driving innovation. If you would like to read the studies cited in the cast they can be found here:
    Fava and Davidson, 1996: https://pubmed.ncbi.nlm.nih.gov/8827185/
    Rush, 2006: https://pubmed.ncbi.nlm.nih.gov/17074942/
    Samples, 2016: https://ps.psychiatryonline.org/doi/pdfplus/10.1176/appi.ps.201400021
    Pratt, 2017: https://www.cdc.gov/nchs/products/databriefs/db283.htm
    Wu, 2005: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320475/
    Liu, 2006: https://www.sciencedirect.com/science/article/pii/S0010440X11000216
    Wu, 2006: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720767/
    I also highly recommend reading this paper for a brief overview of the history of mental health therapies beyond what I had time to mention in the cast:
    Hillhouse, 2015: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428540/
    27 min
  • Episode 2: A Brief History of Ibogaine and 18-MC
    In this episode we examine the initial development of 18-MC from ibogaine and review three of the pioneering studies performed by Dr. Stanley Glick that allowed future research into 18-MC to be possible.
    If you would like to read the 1991 study it can be found here: https://www.ncbi.nlm.nih.gov/pubmed/1868880
    If you would like to read the 1996 study it can be found here: https://www.ncbi.nlm.nih.gov/pubmed/8782860
    If you would like to read the 2000 study it can be found here: https://www.ncbi.nlm.nih.gov/pubmed/11085336 
    I have also done a short write up summarizing the 2000 paper which can be found here: https://www.docdroid.net/MoP6P2V/18-mc-analysis-of-efficacy-and-safety-pdf
    17 min
  • Episode 1: 18-MC Phase I Clinical Trial
    An analysis of Mind Medicine's recently initiated clinical trial investigating the safety of 18-methoxycoronaridine (18-MC) for use in a human population. 
    The study design can be found here: https://clinicaltrials.gov/ct2/show/NCT04292197
    18 min

About Expanding Psych

From the publisher's feed

Expanding Psych is dedicated to providing updates on studies and policies involving experimental psychedelic therapies in the treatment of mental health disorders from a pharmacist to be.